Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Wholesale trade tags : Adhd save search
ABVC BioPharma Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study
Published: 2023-12-07 (Crawled : 13:30) - globenewswire.com
ABVC | $0.9899 -5.72% -6.07% 160K
|
Wholesale Trade
|
| O: -1.48%
H: 2.26%
C: -6.02%
treatment biopharma adhd study
ABVC BioPharma Receives U.S. Patent for ADHD Treatment, a $32 Billion Market
Published: 2023-11-21 (Crawled : 13:30) - globenewswire.com
ABVC | $0.9899 -5.72% -6.07% 160K
|
Wholesale Trade
|
| O: 14.8%
H: 16.84%
C: -6.32%
patent biopharma adhd market
ABVC BioPharma Entered Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million
Published: 2023-10-26 (Crawled : 13:00) - globenewswire.com
ABVC | $0.9899 -5.72% -6.07% 160K
|
Wholesale Trade
|
| O: 289.41%
H: 1.21%
C: -61.33%
license biopharma global adhd
ABVC BioPharma Announces Completion of Subject Recruitment for Interim Analysis on ADHD Phase IIb Clinical Study
Published: 2023-10-17 (Crawled : 12:30) - globenewswire.com
ABVC | $0.9899 -5.72% -6.07% 160K
|
Wholesale Trade
|
| O: -3.6%
H: 1.06%
C: -7.0%
biopharma adhd study
ABVC BioPharma Provides Updates on ADHD Phase IIb Clinical Study
Published: 2023-08-23 (Crawled : 12:30) - globenewswire.com
ABVC | $0.9899 -5.72% -6.07% 160K
|
Wholesale Trade
|
| O: -5.1%
H: 10.22%
C: 2.15%
biopharma adhd study
ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Enrolled at UCSF
Published: 2023-06-12 (Crawled : 12:00) - globenewswire.com
ABVC | $0.9899 -5.72% -6.07% 160K
|
Wholesale Trade
|
| O: 3.32%
H: 0.0%
C: 0.0%
biopharma adhd study
ABVC BioPharma ABV-1505 ADHD Phase IIa Results Presented at 2023 APSARD Conference
Published: 2023-01-19 (Crawled : 14:20) - biospace.com/
ABVC | $0.9899 -5.72% -6.07% 160K
|
Wholesale Trade
|
| O: 3.29%
H: 5.06%
C: -1.25%
abv-1505 biopharma conference adhd results
ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Study Update and Announces UCSF Institutional Review Board Approval
Published: 2022-09-23 (Crawled : 13:00) - globenewswire.com
ABVC | $0.9899 -5.72% -6.07% 160K
|
Wholesale Trade
|
| O: 2.42%
H: 25.3%
C: 10.06%
biopharma adhd approval review update study
ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Update
Published: 2022-07-13 (Crawled : 13:20) - biospace.com/
ABVC | $0.9899 -5.72% -6.07% 160K
|
Wholesale Trade
|
| O: 2.94%
H: 0.63%
C: -5.9%
biopharma adhd update
ABVC BioPharma Announces Enrollment Progress for ADHD Phase II Part 2 Clinical Study
Published: 2022-06-01 (Crawled : 22:00) - biospace.com/
ABVC | $0.9899 -5.72% -6.07% 160K
|
Wholesale Trade
|
| O: -1.01%
H: 4.59%
C: 3.32%
biopharma adhd
ABVC BioPharma ADHD Phase II Part 2 Clinical Study First Subject Treated
Published: 2022-05-10 (Crawled : 13:20) - biospace.com/
ABVC | $0.9899 -5.72% -6.07% 160K
|
Wholesale Trade
|
| O: 2.0%
H: 9.19%
C: 6.11%
biopharma adhd
ABVC BioPharma Completes Site Initiation Visits and Begins Enrollments for ADHD Phase II Part 2 Clinical Study
Published: 2022-04-28 (Crawled : 19:00) - biospace.com/
ABVC | $0.9899 -5.72% -6.07% 160K
|
Wholesale Trade
|
| O: 0.87%
H: 2.16%
C: 2.16%
biopharma adhd enroll
ABVC BioPharma Announces Principal Investigator Meeting for Phase II Part 2 ADHD Clinical Study
Published: 2022-02-02 (Crawled : 14:00) - biospace.com/
ABVC | $0.9899 -5.72% -6.07% 160K
|
Wholesale Trade
|
| O: 0.39%
H: 0.0%
C: 0.0%
biopharma ces adhd
Central IRB Approved for ABV-1505 Phase II Part II in Taiwan Sites
Published: 2021-10-27 (Crawled : 14:00) - biospace.com/
ABVC | $0.9899 -5.72% -6.07% 160K
|
Wholesale Trade
|
| O: -1.2%
H: 2.85%
C: -2.03%
adhd
ABVC BioPharma Completes Site Selection for ABV-1505 ADHD Phase II Part 2 Clinical Study
Published: 2021-09-13 (Crawled : 16:00) - biospace.com/
ABVC | $0.9899 -5.72% -6.07% 160K
|
Wholesale Trade
|
| O: 4.05%
H: 0.53%
C: -10.18%
biopharma adhd
ABVC BioPharma Announces New PCT Filings for MDD and ADHD Treatments
Published: 2021-09-01 (Crawled : 13:00) - globenewswire.com
ABVC | $0.9899 -5.72% -6.07% 160K
|
Wholesale Trade
|
| O: 40.0%
H: 17.0%
C: -11.58%
treatment biopharma adhd
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.